{"id":6325,"date":"2025-08-25T13:26:22","date_gmt":"2025-08-25T13:26:22","guid":{"rendered":"https:\/\/blog.mukundmohan.online\/?p=6325"},"modified":"2025-08-25T13:26:22","modified_gmt":"2025-08-25T13:26:22","slug":"hims-and-hers-deep-dive-and-2025-outlook-hims","status":"publish","type":"post","link":"https:\/\/blog.mukundmohan.online\/index.php\/2025\/08\/25\/hims-and-hers-deep-dive-and-2025-outlook-hims\/","title":{"rendered":"Hims and Hers – Deep dive and 2025 outlook $HIMS"},"content":{"rendered":"\n

Company Overview<\/strong><\/h2>\n\n\n\n

Founded in 2017, Hims &\u202fHers Health, Inc. is a public telehealth and e\u2011commerce platform (NYSE: HIMS) offering personalized, direct-to-consumer healthcare. It enables customers to access licensed providers via an intake process and delivers medications and wellness products discreetly through partner pharmacies. While starting with men\u2019s sexual health and hair care, the brand has expanded into services for women, mental health, skincare, weight loss, and more. Operating across the U.S. and U.K., it champions accessible, digital-first care. The company is headquartered in San Francisco, California.<\/p>\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

Most Recent Earnings (Q2 2025)<\/strong><\/h2>\n\n\n\n

Revenue:<\/strong> $544.8 million, a 73% year-over-year increase from $315.6 million in Q2 2024.<\/p>\n\n\n\n

Net Income:<\/strong> $42.5 million; Adjusted EBITDA:<\/strong> $82.2 million (more than double vs. Q2 2024).<\/p>\n\n\n\n

Subscribers:<\/strong> Over 2.4 million, up ~31%.<\/p>\n\n\n\n

Guidance:<\/strong> For Q3 2025 \u2014 Revenue expected at $570M\u2013$590M; Adj. EBITDA of $60M\u2013$70M. For full-year 2025 \u2014 Revenue guidance is $2.3B\u2013$2.4B; Adj. EBITDA $295M\u2013$335M.  <\/p>\n\n\n\n

EPS:<\/strong> Reported EPS was $0.17 vs. consensus estimates ranging from ~$0.18\u2013$0.21\u2014resulting in a modest miss.  <\/p>\n\n\n\n

\n\n\n\n

Founding, Funding, Products & Headquarters<\/strong><\/h2>\n\n\n\n

Founded in 2017 by Jack Abraham, Andrew Dudum, and Hilary Coles through Atomic Labs, Hims raised $100\u202fmillion in its Series\u202fC in January 2019, enabling it to reach unicorn status with expansion into the UK. It went public in early 2021 via a SPAC merger, achieving a valuation around $1.6 billion.\u202f <\/p>\n\n\n\n

Products initially focused on men\u2019s sexual health and hair loss (e.g., sildenafil, minoxidil). In 2018, it launched Hers for women\u2019s health (birth control, flibanserin), followed by mental health services (e.g., group therapy) in 2020. In 2024, it added compounded GLP\u20111 weight-loss treatments (less expensive but not FDA-reviewed), though the partnership with Novo Nordisk ended in 2025.\u202f <\/p>\n\n\n\n

Headquartered in San Francisco, CA \u2014 the company serves the U.S. and the U.K., and is expanding internationally.\u202f <\/p>\n\n\n\n

\n\n\n\n

Market & Growth Expectations<\/strong><\/h2>\n\n\n\n

Hims operates in the booming telehealth and wellness markets, encompassing prescription medications, OTC products, and digital care across multiple health domains. The U.S. telehealth market is projected to grow significantly, with increasing consumer preference for remote care. Hims\u2019 strategy \u2014 personalization, digital-first delivery, and multiple specialty verticals \u2014 positions it well. They project revenue to reach $6.5\u202fbillion by 2030<\/strong>, with EBITDA of $1.3\u202fbillion, highlighting massive long-term potential.\u202f <\/p>\n\n\n\n

\n\n\n\n

Competitors<\/strong><\/h2>\n\n\n\n

Key competitors include other telehealth\/wellness platforms and online pharmacies offering similar services \u2014 e.g., Roman, Nurx, and broader telehealth providers like Teladoc. These firms also target sexual health, mental health, and skincare segments through digital-first channels.<\/p>\n\n\n\n

\n\n\n\n

Differentiation<\/strong><\/h2>\n\n\n\n

Hims distinguishes itself with a multi-specialty platform (vs. competitors often targeting single categories), focus on personalized treatment pathways, and strong branding across genders. Its user-friendly intake process, ongoing messaging, and access to curated content and care set it apart.<\/p>\n\n\n\n

\n\n\n\n

Management Team<\/strong><\/h2>\n\n\n\n
    \n
  • Andrew Dudum (CEO, Co\u2011Founder):<\/strong>\u00a0Visionary behind the mission to make healthcare accessible and personalized.\u202f\u00a0<\/li>\n\n\n\n
  • Yemi Okupe (CFO):<\/strong>\u00a0Oversees financial strategy, budget management, and earnings results.\u202f\u00a0<\/li>\n\n\n\n
  • Mike Chi (Chief Growth Officer)<\/strong>\u00a0and\u00a0Melissa Baird (COO):<\/strong>\u00a0Key leaders supporting company expansion and operations.\u202f\u00a0<\/li>\n<\/ul>\n\n\n\n
    \n\n\n\n

    5-Year Financial Performance<\/strong><\/h2>\n\n\n\n

    From 2020 to 2024, revenue surged from ~$149 million to $1.48\u202fbillion \u2014 nearly a 10\u00d7 increase. The compound annual growth rate (CAGR) is exceptionally strong (well beyond 50%). EPS also improved from negative\/low levels to ~$0.80 trailing EPS in the past year. The firm reached net profitability and strong Adjusted EBITDA margins (full-year guidance for 2025 suggests ~13\u201314% margin).\u202f <\/p>\n\n\n\n

    Balance-sheet-wise, the company is generating positive cash flow, with a strong net-income trajectory. It\u2019s no longer in high-burn startup mode, with actual profits and subscriber growth reinforcing its financial strength.<\/p>\n\n\n\n

    \n\n\n\n

    Bull Case<\/strong><\/h2>\n\n\n\n
      \n
    • Exceptional growth across multiple verticals, scaling revenue from ~$150M to $1.48B in four years.<\/li>\n\n\n\n
    • Proven ability to deliver personalized care at scale, boosting loyalty and retention (e.g., 2.4 million subscribers, usage up 31%).<\/li>\n\n\n\n
    • Large runway ahead, with $6.5B revenue target by 2030 \u2014 significant upside potential.<\/li>\n<\/ul>\n\n\n\n
      \n\n\n\n

      Bear Case<\/strong><\/h2>\n\n\n\n
        \n
      • Heavy reliance on weight-loss (GLP\u20111) segment, which faces regulatory scrutiny and partner instability (e.g., Novo Nordisk ended partnership).\u202f\u00a0<\/li>\n\n\n\n
      • Recent Q2 results included a revenue miss and GLP\u20111 revenue decline, prompting investor caution.\u202f\u00a0<\/li>\n\n\n\n
      • Rich valuation (P\/E > 55) raises risk if growth slows or competition intensifies.<\/li>\n<\/ul>\n\n\n\n

        The stock is in a bearish stage 4 markdown on the monthly charts, and is showing early reversal in the $41 zone but might fall again to the $37 on the weekly chart. The daily chart is reversing with an expected move to $49 range. We would be early buyers on dips.<\/p>\n\n\n\n

        \"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

        Company Overview Founded in 2017, Hims &\u202fHers Health, Inc. is a public telehealth and e\u2011commerce platform (NYSE: HIMS) offering personalized, direct-to-consumer healthcare. It enables customers to access licensed providers via an intake process and delivers medications and wellness products discreetly through partner pharmacies. While starting with men\u2019s sexual health and hair care, the brand has…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[11],"tags":[],"class_list":["post-6325","post","type-post","status-publish","format-standard","hentry","category-stocks"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/blog.mukundmohan.online\/index.php\/wp-json\/wp\/v2\/posts\/6325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.mukundmohan.online\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.mukundmohan.online\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.mukundmohan.online\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.mukundmohan.online\/index.php\/wp-json\/wp\/v2\/comments?post=6325"}],"version-history":[{"count":1,"href":"https:\/\/blog.mukundmohan.online\/index.php\/wp-json\/wp\/v2\/posts\/6325\/revisions"}],"predecessor-version":[{"id":6328,"href":"https:\/\/blog.mukundmohan.online\/index.php\/wp-json\/wp\/v2\/posts\/6325\/revisions\/6328"}],"wp:attachment":[{"href":"https:\/\/blog.mukundmohan.online\/index.php\/wp-json\/wp\/v2\/media?parent=6325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.mukundmohan.online\/index.php\/wp-json\/wp\/v2\/categories?post=6325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.mukundmohan.online\/index.php\/wp-json\/wp\/v2\/tags?post=6325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}